Le Lézard
Classified in: Health
Subject: TRI

UMF|PerfectCLEAN's KLORESEtm Disinfectant and PerfectCLEAN Wiper Eliminate C. auris in Less Than One Minute


Powerful combination of KLORESE and PerfectCLEAN wiper is essential in the battle against deadly fungal infections

NORTHBROOK, Ill., April 30, 2024 /PRNewswire/ -- Independent testing shows that UMF|PerfectCLEAN's KLORESEtm cleaner-disinfectant combined with a PerfectCLEAN wiper eliminates the deadly fungus Candida auris (C. auris) in less than one minute. Performed by leading contract services organization Integrated Pharma Services, the testing is further proof that KLORESE and PerfectCLEAN are the perfect combination for cleaning and disinfecting any surface in a healthcare facility.

C. auris on the rise in healthcare
Research indicates that a rise in severe fungal infections such as C. auris has resulted in more than 150 million cases annually and almost 1.7 million fatalities globally. According to the World Health Organization (WHO), multi-drug resistant Candida species including C. auris cause many preventable healthcare-associated infections (pHAIs).

Recognizing such fungal infections as a widespread threat to the entire healthcare system, the WHO issued a call to action for the healthcare community to protect people from such fungi. Cleaning and disinfecting patient care environments are primary infection control measures for preventing the transmission of C. auris in healthcare settings.

KLORESE + PerfectCLEAN: A powerful combination for eliminating C. auris
"Our testing results demonstrated that a PerfectCLEAN wiper combined with KLORESE, an EPA-registered cleaner-disinfectant, is capable of complete removal of C. auris from surfaces, retaining it in the wiper where it is exposed to KLORESE, which eliminated 100% of the C. auris in one minute or less," said Dr. Mina Izadjoo, president and chief science officer at Integrated Pharma Services.

KLORESE and a PerfectCLEAN wiper help eliminate and prevent C. auris by:

"The result of this testing further validates KLORESE combined with PerfectCLEAN wipers as essential in the fight against pHAIs such as C. auris," said UMF|PerfectCLEAN CEO George Clarke. "With this powerful combination, Environmental Services teams can safely, effectively, and efficiently clean and disinfect surfaces throughout the healthcare facility. KLORESE and the PerfectCLEAN wiper are the only tools required to clean and disinfect any surface in any room."

Added Clarke, "While patient health and safety is the utmost priority, the cost to treat C. auris and other pHAIs is considerable due to extended hospital stays, intensive care, diagnostic tests, and expensive medications. Effective environmental cleaning and disinfection help mitigate such costs by mitigating the risk of such infections."

Reach out to learn how KLORESE and PerfectCLEAN can help your organization eliminate and prevent pHAIs such as C. auris.

About UMF|PerfectCLEAN
UMF|PerfectCLEAN is the leader in the research and development of high-performance products, programs, and training for the infection prevention and commercial cleaning markets. Through extensive testing, exhaustive analysis, and the commitment of significant human and financial resources, UMF|PerfectCLEAN has merged new technologies with innovative product designs that are reinventing cleantm. UMF|PerfectCLEAN is a proud strategic partner of the Association for Professionals in Infection Control and Epidemiology (APIC). LinkedIn

SOURCE UMF Corporation


These press releases may also interest you

at 01:18
. Hansa Biopharma, "Hansa" (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant Congress (ATC), the joint annual meeting of the American Society of Transplant Surgeons (ASTS) and the American...

at 01:05
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for inavolisib, an investigational oral therapy, in combination with...

at 01:05
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that in an abstract published on 14 May 2024 for the European Hematology Association 2024 Congress on SAR443579/IPH6101, submitted by...

at 00:01
Celltrion USA announced today...

at 00:01
SonarMD today presented positive results from two large, longitudinal studies evaluating several major drivers of medical costs in people living with Inflammatory Bowel Disease (IBD) ? defined as people living with ulcerative colitis or Crohn's...

at 00:00
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it signed a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA) to begin discussions on the creation of an innovative cell therapy...



News published on and distributed by: